Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1

Conditions

Colorectal Neoplasms 36Colonic Neoplasms 10Rectal Neoplasms 8Neoplasm Metastasis 8Neoplasms 5Pancreatic Neoplasms 2Carcinoma, Neuroendocrine 2Adenocarcinoma 2Stomach Neoplasms 1Ras-mutated Metastatic Colorectal Cancer 1Pancreatic Adenocarcinoma Metastatic 1Ovarian Neoplasms 1Neuroendocrine Tumors 1Metastatic Pancreatic Ductal Adenocarcinoma 1Metastatic Colorectal Adenocarcinoma 1Liver Metastasis Colon Cancer 1Gastrointestinal Neoplasms 1Exanthema 1Carcinoma, Basal Cell 1Carcinoma 1CRC 1Advanced Cancer 1

Interventions

lutetium Lu 177 dotatate 15Everolimus 11Nivolumab 10pembrolizumab 9Temozolomide 9Capecitabine 7cabozantinib 6Sunitinib 6lenvatinib 5lanreotide 4gallium Ga 68 dotatate 4Ipilimumab 4Etoposide 4Carboplatin 4177Lu-octreotide, DOTA(0)-Tyr(3)- 4telotristat ethyl 3pazopanib 3avelumab 3Octreotide 3Magnetic Resonance Spectroscopy 3Injections 3Cyclophosphamide 3Cisplatin 3Bevacizumab 3surufatinib 2sintilimab 2fosbretabulin 2fludarabine 2Specimen Handling 2Sorafenib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Neuroendocrine Tumors × IFL protocol × Clear all
NCT05879055 2024-12-19

A Study of PM8002 in Combination With Chemotherapy in Patients With NEN

Biotheus Inc.

Phase 2 Recruiting
60 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡